Citius Oncology CTOR
NASDAQ CTOR
$0.70 +0.03 (+4.32%)
As of: Oct 21, 2026 · 11:19 AM EDT

Citius Oncology (CTOR) Net Margin (2025 - 2026)

Updated

Citius Oncology (CTOR) recorded Net Margin of -597.40% in fiscal Q3 2026 (quarter ended Jun 30, 2026), up 998.58 percentage points from the prior quarter.

Analysis

Citius Oncology (CTOR) Net Margin (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,134.69 Bn 1,103.27 Bn 19.71 Bn 30.88%
2 Johnson & Johnson 616.29 Bn 534.82 Bn 17.26 Bn 21.86%
3 AbbVie 500.86 Bn 473.97 Bn 12.70 Bn 21.27%
4 Merck 366.77 Bn 321.15 Bn 12.21 Bn -8.04%
5 Novartis Ag 297.69 Bn 261.68 Bn 11.24 Bn 22.65%
6 Astrazeneca 261.39 Bn 235.08 Bn 12.86 Bn 16.30%
7 Amgen 235.52 Bn 190.92 Bn 7.24 Bn 23.62%
8 Gilead Sciences 190.49 Bn 164.69 Bn 6.22 Bn -134.51%
9 Pfizer 169.46 Bn 116.11 Bn 10.94 Bn -1.65%
10 Citius Oncology 75.52 Mn 45.11 Mn 1.00 Mn -597.40%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -597.40%
Mar 31, 2026 -1,595.98%
Dec 31, 2025 -140.31%
API Access

Citius Oncology Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=CTOR&period=max&api_key=YOUR_API_KEY